GC
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
GC (GC Holdings) is a holding company, a parent entity that owns and oversees a group of operating subsidiaries, whose businesses span pharmaceutical manufacturing, blood diagnostics and genetic analysis, healthcare services, and real estate leasing, all listed on KOSPI, Korea's main stock exchange.
Its products and services reach patients, healthcare providers, and other end-users through its subsidiary companies rather than directly. The pharmaceutical manufacturing and distribution arm accounts for the largest share of consolidated revenue, with diagnostics and healthcare services making up most of the remainder.
Summary is AI-generated and may contain errors · figures from DART filings
GC acts as the strategic and portfolio-management parent for its subsidiaries, including its principal operating subsidiary GC Corporation, while the subsidiaries themselves conduct the actual business operations.
GC in five facts
What does GC do?
GC (GC Holdings) is a holding company, a parent entity that owns and oversees a group of operating subsidiaries, whose businesses span pharmaceutical manufacturing, blood diagnostics and genetic analysis, healthcare services, and real estate leasing, all listed on KOSPI, Korea's main stock exchange.
Where is GC listed and in which sector?
GC (Korean name: 녹십자홀딩스) trades under KRX code 005250 on KOSPI, the main board of the Korea Exchange. It is classified in the Industrials sector, Commercial Services.
How large is GC?
Its market capitalisation was US$341.5M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were GC's latest annual revenue and operating profit?
For fiscal year 2025, GC reported revenue of US$1.9B, operating profit of US$27.3M and a net loss of US$31.6M, per its annual report on DART (data retrieved from DART on 2026-09-06). Revenue was up 11.2% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-06
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Change in shares held by the largest shareholderSep 23
- Report on large shareholdings (5% rule) (standard)Sep 23
- Decision to acquire shares/equity in another company
GC disclosed an acquisition of GC WellBeing, worth US$33.6M.
M&A · Mar 31 - [Amended] Change of 30% or more in revenue or profit/loss structure (15% for large companies)
GC updated its previously filed consolidated results for FY2025: revenue of US$1.65B (+11.2% year on year), operating profit of US$24.4M (from a loss a year earlier) and a net loss of US$28.2M.
Earnings · Mar 9 · 2 versions - Cash/in-kind dividend decision
GC declared a cash dividend of US$0.21 per share.
Dividend · Feb 11